Mr. Berns has more than 20 years of industry experience having held executive roles in the pharma and biopharma industries. He most recently served as the president and chief executive officer of Allos Therapeutics.
“We appreciate David’s commitment to Anacor and the many contributions he has made over the past 12 years to help build Anacor into the company it is today,” said Paul Klingenstein, chair of the nominating and governance committee of the Anacor board. “We are delighted to have attracted a proven leader of Paul’s capabilities to assume the role of CEO for the next phase of Anacor’s growth. Having served as Chairman, Paul has a deep knowledge of Anacor’s management team, strategy, partners and development pipeline, thus enabling a smooth transition. Additionally, Paul’s significant commercial and product development experience, combined with his strategic and business development expertise, makes him ideally suited to lead Anacor as we seek to achieve our goals.”